ArticleMolecular genetics & genomic medicine2026
Targeted Carrier Screening for Thalassemia, Hereditary Deafness, and Spinal Muscular Atrophy: A Feasible Approach for Preventing Birth Defects in China's Community Healthcare System.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeted Carrier Screening for Thalassemia, Hereditary Deafness, and Spinal Muscular Atrophy: A Feasible Approach for Preventing Birth Defects in China's Community Healthcare System.Molecular genetics & genomic medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWhile carrier screening is crucial for preventing birth defects, a significant gap exists between comprehensive screening guidelines and the practical barriers-cost, complexity, and compliance-faced by community healthcare in China. This study evaluates the real-world feasibility and clinical effectiveness of a targeted screening program for thalassemia, hereditary deafness, and spinal muscular atrophy in community health settings in China.
methodsA total of 7068 pregnant women attending the prenatal clinic at Wenzhou Central Hospital underwent genetic carrier screening from February 2020 to June 2024. The screening focused on hotspot variants using NMPA-approved kits. A two-tiered counseling model was implemented, and clinical effectiveness was assessed via a four-year follow-up using hospital and birth defect registries.
resultsThe screening program identified 1067 carriers, with an overall carrier rate of 15.1%. Among 72 couples with pathogenic variants in the same gene, 12 fetuses were found to be at "abnormal risk." Crucially, the four-year follow-up revealed no false-negative cases for the targeted severe conditions, demonstrating high clinical effectiveness and a robust negative predictive value.
conclusionThis targeted screening program is a clinically effective, cost-conscious, and regulatively compliant framework for preventing severe genetic disorders in China. By strategically balancing clinical impact with economic and logistical realities, this model provides a valuable, replicable approach to improving maternal and child health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.